Abstract
Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Current Neuropharmacology
Title: Startle Response Modulation as a Behavioral Tool in Neuropharmacology
Volume: 1 Issue: 2
Author(s): M. Koch and M. Fendt
Affiliation:
Keywords: anxiety, fear, fear-potentiated startle, prepulse inhibition, schizophrenia
Abstract: Behavioral studies in animals are an important part of neuropharmacological research, because they integrate findings from in vitro pharmacology, chemical neuroanatomy and electrophysiology at the systems level, thereby bridging the gap between basic research on one hand, and the development of pharmacological treatment with clinical trials on the other hand. Animal behavioral models of neuropsychiatric diseases (such as fear/anxiety disorders, depression, addiction, or schizophrenia) are, therefore, an eminent part of preclinical neuropharmacology. We review here recent neuropharmacological findings on prepulse inhibition (PPI) and fear-potentiation of the startle response (FPS) as behavioral models for sensorimotor gating deficits in neuropsychiatric disorders and fear/anxiety-related disorders, respectively.
Export Options
About this article
Cite this article as:
Koch M. and Fendt M., Startle Response Modulation as a Behavioral Tool in Neuropharmacology, Current Neuropharmacology 2003; 1 (2) . https://dx.doi.org/10.2174/1570159033477161
DOI https://dx.doi.org/10.2174/1570159033477161 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)
Current Neuropharmacology Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives
Current Medicinal Chemistry On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment
Current Drug Abuse Reviews Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Current Pharmaceutical Design An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia
Current Pharmaceutical Design Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Research Review: Childhood Maltreatment and Executive Functioning During Adolescence
Adolescent Psychiatry Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Function and Expression Pattern of Nonsyndromic Deafness Genes
Current Molecular Medicine FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia
Central Nervous System Agents in Medicinal Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Methadone Maintenance Treatment and Cognitive Function: A Systematic Review
Current Drug Abuse Reviews